{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:14:16Z","timestamp":1768000456662,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007557","name":"California Institute of Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007557","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bbmt.2020.07.004","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T18:58:04Z","timestamp":1594321084000},"page":"1819-1827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Kathryn L.","family":"Bradford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Krajinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Garabedian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kit L.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Bobby","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Candotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald B.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.004_bib0001","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1349-7006.2004.tb03231.x","article-title":"DNA intrastrand cross-link at the 5\u2032-GA-3\u2032 sequence formed by busulfan and its role in the cytotoxic effect","volume":"95","author":"Iwamoto","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0002","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.exphem.2005.12.005","article-title":"Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector","volume":"34","author":"Kahl","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0004","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/mt.2011.312","article-title":"Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys","volume":"20","author":"Tarantal","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0005","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0006","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-13-1960","article-title":"Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization","volume":"20","author":"McCune","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0007","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FTD.0000000000000131","article-title":"Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use","volume":"37","author":"Long-Boyle","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0008","doi-asserted-by":"crossref","first-page":"90852","DOI":"10.18632\/oncotarget.20310","article-title":"GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study","volume":"8","author":"Ansari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0009","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/pgs.13.159","article-title":"Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"14","author":"ten Brink","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0010","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2014.04.005","article-title":"Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics","volume":"19","author":"ten Brink","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187294","article-title":"Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway","volume":"12","author":"El-Serafi","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0012","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/bmt.2015.321","article-title":"Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients","volume":"51","author":"Ansari","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0013","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1399-3046.2008.01098.x","article-title":"Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation","volume":"13","author":"Kim","year":"2009","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0091270006295789","article-title":"Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients","volume":"47","author":"Booth","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/bmt.2009.143","article-title":"Influence of GST gene polymorphisms on busulfan pharmacokinetics in children","volume":"45","author":"Ansari","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0016","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bmt.2012.265","article-title":"Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients","volume":"48","author":"Ansari","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0017","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.bbmt.2010.12.708","article-title":"Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0018","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2011.55","article-title":"Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT","volume":"47","author":"ten Brink","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0019","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/0091270008321940","article-title":"Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation","volume":"48","author":"Johnson","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0020","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/FTD.0b013e3181817428","article-title":"Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients","volume":"30","author":"Zwaveling","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0021","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/1389200215666140202214012","article-title":"Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children","volume":"15","author":"Huezo-Diaz","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0022","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0023","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bbmt.2004.07.010","article-title":"Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation","volume":"10","author":"Tran","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0024","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","article-title":"Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies","volume":"26","author":"Tran","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bmt.1703264","article-title":"Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation","volume":"28","author":"Bolinger","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0026","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.coi.2012.08.008","article-title":"Gene therapy for primary immunodeficiencies: Part 1","volume":"24","author":"Cavazzana-Calvo","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0027","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12026-009-8107-8","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID","volume":"44","author":"Aiuti","year":"2009","journal-title":"Immunol Res"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0028","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0029","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/mt.2013.265","article-title":"Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency","volume":"22","author":"Carbonaro","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0032","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-12-756734","article-title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients","volume":"129","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0033","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.bbmt.2016.04.013","article-title":"Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies","volume":"22","author":"Pasquini","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0034","series-title":"DIFLUCAN\u00ae (Fluconazole) [package insert]","year":"2011"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0035","series-title":"BACTRIM\u2122 sulfamethoxazole and trimethoprim DS (double strength) tablets and tablets USP [package insert]","year":"2013"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0036","first-page":"1013","article-title":"Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1","volume":"7","author":"Lin","year":"1998","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0037","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/carcin\/14.9.1821","article-title":"Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer","volume":"14","author":"Zhong","year":"1993","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0038","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.85.19.7293","article-title":"Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion","volume":"85","author":"Seidegard","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 1","key":"10.1016\/j.bbmt.2020.07.004_bib0039","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/bj3000271","article-title":"Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism","volume":"300","author":"Pemble","year":"1994","journal-title":"Biochem J"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/(SICI)1097-0258(19960330)15:6<647::AID-SIM184>3.0.CO;2-P","article-title":"An asymptotic test for the equality of coefficients of variation from k populations","volume":"15","author":"Feltz","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0041","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJM199605233342104","article-title":"Brief report: Hepatic dysfunction as a complication of adenosine deaminase deficiency","volume":"334","author":"Bollinger","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0042","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ng0795-279","article-title":"Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death","volume":"10","author":"Migchielsen","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0043","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1073\/pnas.92.9.3673","article-title":"Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice","volume":"92","author":"Wakamiya","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0044","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0045","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/blood-2012-02-408591","article-title":"Gene therapy\/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction","volume":"120","author":"Carbonaro","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0046","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0047","unstructured":"Hughes HK, Kahl LK. The Harriet Lane Handbook: A Manual for Pediatric House Officers. 21st ed.Philadelphia, PA: Elsevier; 2018."},{"key":"10.1016\/j.bbmt.2020.07.004_bib0048","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00689702","article-title":"Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology","volume":"28","author":"Hassan","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0049","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1177\/0091270010382915","article-title":"Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients","volume":"51","author":"Abbasi","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0050","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1067\/mcp.2002.124518","article-title":"Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation","volume":"71","author":"Bredschneider","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0051","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/FTD.0000000000000180","article-title":"Glutathione transferase gene variants influence busulfan pharmacokinetics and outcome after myeloablative conditioning","volume":"37","author":"Bremer","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.bbmt.2020.07.004_bib0052","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2011-01-329359","article-title":"Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency","volume":"118","author":"Sokolic","year":"2011","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:36Z","timestamp":1761059616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1083879120304134"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.004","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}